GABAergic and Endocannabinoid Dysfunction in Anxiety - Future Therapeutic Targets?

E-ISSN： 1873-4286|14|33|3508-3517

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.33, 2008-11, pp. : 3508-3517

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Neuropeptides as Therapeutic Targets in Anxiety Disorders

Current Pharmaceutical Design, Vol. 18, Iss. 35, 2012-12 ,pp. : 5709-5727

Bentham Science Publishers

Access to resources Recommend Favorite

Endothelial Dysfunction in Diabetes: From Mechanisms to Therapeutic Targets

Current Medicinal Chemistry, Vol. 16, Iss. 1, 2009-01 ,pp. : 94-112

Bentham Science Publishers

Access to resources Recommend Favorite

Current and Future Therapeutic Targets of Rheumatoid Arthritis

Anti-Infective Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Infective Agents), Vol. 10, Iss. 2, 2011-04 ,pp. : 92-120

Bentham Science Publishers

Access to resources Recommend Favorite

Current and Future Therapeutic Targets of Rheumatoid Arthritis

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents), Vol. 10, Iss. 2, 2011-04 ,pp. : 92-120

Bentham Science Publishers

Access to resources Recommend Favorite

Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders

By Holmes A. Heilig M. Rupniak N.M.J. Steckler T. Griebel G.

Trends in Pharmacological Sciences, Vol. 24, Iss. 11, 2003-11 ,pp. : 580-588

Elsevier

Access to resources Recommend Favorite